Publication
Inhalable chitosan microparticles for simultaneous delivery of isoniazid and rifabutin in lung tuberculosis treatment
dc.contributor.author | Cunha, Ludmylla | |
dc.contributor.author | Rodrigues, Susana | |
dc.contributor.author | Rosa Da Costa, Ana | |
dc.contributor.author | Faleiro, Maria Leonor | |
dc.contributor.author | Buttini, Francesca | |
dc.contributor.author | Grenha, Ana | |
dc.date.accessioned | 2020-04-02T10:10:52Z | |
dc.date.available | 2020-08-01T00:30:11Z | |
dc.date.issued | 2019 | |
dc.description.abstract | The direct delivery of antibiotics to the lung has been considered an effective approach to treat pulmonary tuberculosis, which represents approximately 80% of total cases. In this sense, this work aimed at producing inhalable chitosan microparticles simultaneously associating isoniazid and rifabutin, for an application in pulmonary tuberculosis therapy. Spray-dried chitosan microparticles were obtained with adequate flow properties for deep lung delivery (aerodynamic diameter of 4 µm) and high drug association efficiencies (93% for isoniazid and 99% for rifabutin). The highest concentration of microparticles that was tested (1 mg/mL) decreased the viability of macrophage-differentiated THP-1 cells to around 60% after 24 h exposure, although no deleterious effect was observed in human alveolar epithelial (A549) cells. The release of LDH was, however, increased in both cells. Chitosan microparticles further evidenced capacity to activate macrophage-like cells, inducing cytokine secretion well above basal levels. Moreover, the propensity of macrophages to internalize microparticles was demonstrated, with uptake levels over 90%. Chitosan microparticles also inhibited bacterial growth by 96%, demonstrating that the microencapsulation preserved drug antibacterial activity in vitro. Overall, the obtained data suggest the potential of chitosan microparticles for inhalable lung tuberculosis therapy. | pt_PT |
dc.description.sponsorship | PTDC/DTP-486 FTO/0094/2012 | pt_PT |
dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
dc.identifier.doi | 10.1080/03639045.2019.1608231 | pt_PT |
dc.identifier.issn | 0363-9045 | |
dc.identifier.uri | http://hdl.handle.net/10400.1/13681 | |
dc.language.iso | eng | pt_PT |
dc.peerreviewed | yes | pt_PT |
dc.publisher | Taylor & Francis | pt_PT |
dc.subject | A549 cells | pt_PT |
dc.subject | Administration | pt_PT |
dc.subject | Antitubercular agents | pt_PT |
dc.subject | Cell Line | pt_PT |
dc.subject | Chitosan | pt_PT |
dc.subject | Drug carriers | pt_PT |
dc.subject | Humans | pt_PT |
dc.subject | Isoniazid | pt_PT |
dc.subject | Lung | pt_PT |
dc.subject | Macrophages | pt_PT |
dc.subject | Nanoparticles | pt_PT |
dc.subject | Particle size | pt_PT |
dc.subject | Rifabutin | pt_PT |
dc.subject | Tuberculosis | pt_PT |
dc.subject | Tumor | pt_PT |
dc.subject | Alveolar | pt_PT |
dc.subject | Inhalation | pt_PT |
dc.subject | Pulmonary | pt_PT |
dc.title | Inhalable chitosan microparticles for simultaneous delivery of isoniazid and rifabutin in lung tuberculosis treatment | pt_PT |
dc.type | journal article | |
dspace.entity.type | Publication | |
oaire.awardURI | info:eu-repo/grantAgreement/FCT/5876/UID%2FMulti%2F04326%2F2013/PT | |
oaire.awardURI | info:eu-repo/grantAgreement/FCT/5876/UID%2FBIM%2F04773%2F2013/PT | |
oaire.citation.endPage | 1320 | pt_PT |
oaire.citation.issue | 8 | pt_PT |
oaire.citation.startPage | 1313 | pt_PT |
oaire.citation.title | Drug Development and Industrial Pharmacy | pt_PT |
oaire.citation.volume | 45 | pt_PT |
oaire.fundingStream | 5876 | |
oaire.fundingStream | 5876 | |
person.familyName | Cunha | |
person.familyName | Rodrigues | |
person.familyName | Rosa da Costa | |
person.familyName | Faleiro | |
person.familyName | Grenha | |
person.givenName | Ludmylla Costa | |
person.givenName | Susana | |
person.givenName | Ana M | |
person.givenName | Maria Leonor | |
person.givenName | Ana | |
person.identifier | 305029 | |
person.identifier | 252666 | |
person.identifier.ciencia-id | 9D1A-6537-0383 | |
person.identifier.ciencia-id | A418-A85E-5DB1 | |
person.identifier.ciencia-id | 281D-5E01-F09A | |
person.identifier.ciencia-id | 091C-0D58-7225 | |
person.identifier.orcid | 0000-0003-2620-5760 | |
person.identifier.orcid | 0000-0002-0329-4265 | |
person.identifier.orcid | 0000-0003-0225-9537 | |
person.identifier.orcid | 0000-0002-3878-6948 | |
person.identifier.orcid | 0000-0002-2136-1396 | |
person.identifier.rid | E-2165-2012 | |
person.identifier.rid | H-1392-2017 | |
person.identifier.scopus-author-id | 55125292100 | |
person.identifier.scopus-author-id | 53986075100 | |
person.identifier.scopus-author-id | 6507927018 | |
person.identifier.scopus-author-id | 8607930100 | |
project.funder.identifier | http://doi.org/10.13039/501100001871 | |
project.funder.identifier | http://doi.org/10.13039/501100001871 | |
project.funder.name | Fundação para a Ciência e a Tecnologia | |
project.funder.name | Fundação para a Ciência e a Tecnologia | |
rcaap.rights | openAccess | pt_PT |
rcaap.type | article | pt_PT |
relation.isAuthorOfPublication | 90a94579-d2cb-47a7-8f9f-991b29dfa9d1 | |
relation.isAuthorOfPublication | f7e806c8-708d-4caf-9b95-cfe9f3b06e8e | |
relation.isAuthorOfPublication | 0ca8c16f-6881-4662-bafc-cc51c5ce8d88 | |
relation.isAuthorOfPublication | 5361e29a-3b79-4ce8-9f87-0c667d60588d | |
relation.isAuthorOfPublication | 1bd4d8f1-40e5-45af-b1e8-4b8e73a6a70d | |
relation.isAuthorOfPublication.latestForDiscovery | f7e806c8-708d-4caf-9b95-cfe9f3b06e8e | |
relation.isProjectOfPublication | 868b4818-3efa-4edb-9202-c464d64fd38f | |
relation.isProjectOfPublication | e13142f2-37b8-4b5a-b2cd-352e62003184 | |
relation.isProjectOfPublication.latestForDiscovery | e13142f2-37b8-4b5a-b2cd-352e62003184 |